Carl Regillo, MD was the principal investigator in clinical trials of Genentech’s Susvimo Port Delivery System, an implant that will revolutionize care for neovascular age-related macular degeneration.
“Susvimo is going to be a game-changer for the care of patients with retinal disease,” said Dr. Regillo.
Read more about Dr. Regillo’s key role in the research and clinical trials of the Port Delivery System at: https://bit.ly/3pUVqoT
